Abstract
Construct expression vectors of pCMV-DR4-HA and pCMV-PRMT5-Flag, and transfect them into HEK293 cells to identify the interaction between TRAIL-R1 and PRMT5 and the molecular mechanism underlying DR4-mediated inhibition of chemokine CCL20 release via TRAIL receptor 1 (DR4). Inflammatory cytokine was detected by RT-PCR and ELISA after TRAIL-R1 and/or PRMT5 transfection, respectively. NF-κB activity was detected by Dual Luciferase Reporter Gene Assay. ERK1/2 phosphorylation was analyzed by Western blot. PRMT5 could inhibit DR4-activated NF-κB activity and ERK1/2 phosphorylation. PRMT5 could inhibit NF-κB activition, ERK1/2 phosphorylation as well as CCL20 secretion via binding with DR4 in HEK293 cell, suggesting that PRMT5 may involve in DR4 dependent immune regulation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wiley S R, Schooley K, Smolak P J, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3: 673–682
Walczak H, Miller R E, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 1999, 5: 157–163
Ashkenazi A, Pai R C, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 1999, 104: 155–162
Park S J, Bijangi-Vishehsaraei K, Safa A R. Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in p-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells. Int J Biochem Mol Biol, 2010, 1: 90–100
Park S, Zhao D, Hatanpaa K J, et al. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res, 2009, 69: 4107–4111
Mowen K A, Schurter B T, Fathman J W, et al. Arginine methylation of NIP45 modulates cytokine gene expression in effector T lymphocytes. Mol Cell, 2004, 15: 559–571
Tanaka H, Hoshikawa Y, Oh-Hara T, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-κB activation. Mol Cancer Res, 2009, 7: 557–569
Trauzold A, Wermann H, Arlt A, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene, 2001, 20: 4258–4269
Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the AKT and ERK pathways. Circulation, 2003, 107: 2250–2256
Tang W H, Wang W M, Zhang Y X, et al. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J, 2009, 276: 581–593
Tang W H, Wang W M, Zhang Y X, et al. TRAIL receptor mediates inflammatory cytokine release in an NF-κB-dependent manner. Cell Res, 2009, 19: 758–767
Wei W, Wang D S, Shi J, et al. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces chemotactic migration of monocytes via a death receptor 4-mediated RhoGTPase pathway. Mol Immunol, 2010, 47: 2475–2484
Demedts I K, Bracke K R, Pottelberge G V, et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2007, 175: 998–1005
Tao J, Li L, Tan Z, et al. Up-regulation of CC chemokine ligand 20 and its receptor CCR6 in the lesional skin of early systemic sclerosis. Eur J Dermatol, 2011, 21: 731–736
Liu J L, Zhang N, Li Q, et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One, 2011, 29: e19495
Rubie C, Frick V O, Ghadjar P, et al. Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastasis. World J Gastroenterol, 2011, 26: 3109–3116
Johnstone R W, Frew A J, Smyth M J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer, 2008, 8: 782–798
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Wang, D., Liu, D., Gao, J. et al. PRMT5 suppresses DR4-mediated CCL20 release via NF-κB pathway. Chin. Sci. Bull. 57, 4351–4355 (2012). https://doi.org/10.1007/s11434-012-5511-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-012-5511-6